Monday, April 01, 2024 3:14:48 PM
“AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”
GO4AWILDRIDE
STOCK MARKET SUCKS
Recent ANTX News
- AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights • Business Wire • 03/28/2024 08:10:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/13/2024 10:11:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 12:01:31 PM
- AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease • Business Wire • 02/12/2024 11:45:00 AM
- AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference • Business Wire • 01/30/2024 09:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 11:19:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:03:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:08:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:59:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 11:06:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 11:05:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/02/2024 09:45:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/02/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 11:57:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:10:14 PM
- AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights • Business Wire • 11/09/2023 09:05:00 PM
- AN2 Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 11/06/2023 12:00:00 PM
- AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease • Business Wire • 10/18/2023 11:00:00 AM
- AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023 • Business Wire • 10/11/2023 04:01:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 11:21:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/02/2023 08:10:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:40:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/29/2023 08:11:11 PM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM